Roche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage Pipeline
Q4 results reinforce our positive outlook on Roche, highlighting the company's resilience and strategic advancements. Solid performance of Ocrevus and Vabysmo are key drivers of near-term top-line sales. Roche also unveiled a new class of next-generation sequencing technology. Roche's late-stage pipeline supports our belief that there is still room for growth. With a solid balance sheet and a valuation discount, this company is a buy.
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG released its Q4 and full-year 2024 earnings yesterday. I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS grew in the double-digit percentages. Roche had 16 “blockbuster” drugs in 2024, but some face patent expirations in the near-to-medium term, while other, newer products are expected to offset any losses.
Roche Holding AG (RHHBY) Q4 2024 Earnings Call Transcript
Roche Holding AG (OTCQX:RHHBY) Q4 2024 Earnings Conference Call January 30, 2025 8:00 AM ET Company Participants Thomas Schinecker - CEO Alan Hippe - Chief Financial & Information Officer Teresa Graham - CEO, Roche Pharmaceuticals Matt Sause - CEO, Roche Diagnostics Bruno Eschli - Head, IR Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Sachin Jain - Bank of America Matthew Weston - UBS Simon Baker - Redburn James Quigley - Goldman Sachs Richard Parkes - BNP Rajesh Kumar - HSBC Justin Smith - Bernstein Benjamin Jackson - Jefferies Operator [Starts Abruptly] If you note that the webinar is being recorded. I'd like to inform you that all participants are in listen-only mode, during the call.
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Roche CEO: We had a strong 2024 and expect momentum to carry into 2025
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
Roche sees high single-digit core profit growth in 2025
Swiss drugs and diagnostics company Roche said on Thursday it is targeting an increase in core 2025 earnings per share in a high single-digit percentage range, when adjusted for currency swings.
Roche set to finalise $1.5bn Poseida Therapeutics takeover
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for payment on 65 million shares in Poseida, which specialises in complex immune cell therapies for types of blood cancer.
Roche to complete acquisition of U.S. biopharma company Poseida
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche has no plans for job cuts and business is healthy, CEO says
Swiss pharmaceutical company Roche is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
An experimental Parkinson's drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
